Platform Advantage VBI's evolving in vivo nanoparticle (IVN) technology complements its virus-like particle platform, offering antigen display that may elicit durable immune responses with potentially simpler manufacturing. This creates licensing or co-development opportunities for vaccine developers seeking scalable, particle-based platforms and could broaden VBI's partner base beyond its own vaccine programs.

Strategic Partnerships The Brii Biosciences collaboration, including exclusive APAC rights for BRII-179 and the launch of PreHevbri in APAC, demonstrates VBI's ability to establish region-focused licensing and co-development deals with global pharma. This may help VBI scale commercialization and invites prospective regional partners seeking vaccine assets or manufacturing access in Asia-Pacific.

Clinical Momentum Recent interim tumor response data for VBI-1901 in recurrent glioblastoma indicate a pathway for immuno-oncology collaboration or license-out to biopharma partners looking to bolster their cancer vaccine portfolios. This creates opportunities for co-development, milestone-driven deals, or strategic partnerships with oncology franchises.

Global Footprint VBI's research sites in Ottawa and a manufacturing site in Rehovot, Israel, alongside its Cambridge headquarters, provide a multinational footprint that can support regional clinical trials, manufacturing partnerships, and cross-border supply arrangements. This makes VBI an attractive partner for contract research and contract development/manufacturing organizations seeking diverse geographic access.

Financial Leverage With modest current revenue and external funding activity, VBI may benefit from licensing, milestone-based collaborations, or strategic investments to accelerate its pipeline. This can be framed as value for partners and investors, presenting a lower-risk entry point for co-development of vaccines or immunotherapies in infectious disease and cancer indications.